The role of Mifepristone on First-trimester miscarriage Treatment (MiFirsT) – a double-blind randomized controlled trial

Hospital da Senhora da Oliveira Guimarães0 个研究点目标入组 216 人开始时间: 2020年9月12日最近更新: 2023年8月21日

适应症

试验速览

暂无简介。

•1. Anembryonic or missed first-trimester miscarriage up to 9 weeks of gestation by transvaginal ultrasound (diagnosis criteria according to Society of Radiologists in Ultrasound Multispeciality Consensus Conference on Early First Trimester Diagnosis of Miscarriage and Exclusion of a Viable Intrauterine Pregnancy, October 2012)
•2. Healthy women aged 18 years or older

•1. Diagnosis of inevitable or incomplete miscarriage
•2. Suspicious of ectopic pregnancy or trophoblastic disease
•3. Intrauterine device in place
•4. Allergy to prostaglandins
•5. Medical conditions contraindicating the treatment with misoprostol and/or mifepristone, namely intense vaginal bleeding with severe anemia or hemodynamic instability, suspicious of systemic infection, patients with hemorrhagic disorders or on anticoagulant therapy, patients with porphyria, uncontrolled heart disease, adrenal failure or on concurrent long-term corticosteroid therapy

发起方

Hospital da Senhora da Oliveira Guimarães